Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4954055 | 1.00 | TSHR (0.44) | TSHRHCAR2KEAP1NFE2L2OR51E2 | |
| SCHEMBL4954046 | 1.00 | TSHR (0.44) | TSHRHCAR2KEAP1NFE2L2OR51E2 | |
| SCHEMBL18820281 | 0.94 | TSHR (0.42) | TSHRHCAR2KEAP1NFE2L2 | |
| SCHEMBL8190669 | 0.94 | TSHR (0.42) | TSHRHCAR2KEAP1NFE2L2 | |
| SCHEMBL8190673 | 0.94 | TSHR (0.42) | TSHRHCAR2KEAP1NFE2L2 | |
| SCHEMBL9535027 | 0.93 | TSHR (0.41) | TSHRHCAR2KEAP1NFE2L2 | |
| SCHEMBL9535032 | 0.93 | TSHR (0.41) | TSHRHCAR2KEAP1NFE2L2 | |
| SCHEMBL11722397 | 0.80 | MAPK1 (0.44) | TSHRHCAR2KDM4E | |
| SCHEMBL11725317 | 0.80 | HCAR2 (0.36) | TSHRHCAR2 | |
| SCHEMBL15598874 | 0.80 | MAPK1 (0.44) | TSHRHCAR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017072796-A1 | 2-PYRIDONE BASED COMPOUNDS USEFUL AS POTENTIAL PHOSPHODIESTERASE3A (PDE3A)INHIBITORS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-05-04 | — | — | WO | disclosed |
| WO-2012069680-A1 | METHOD FOR SYNTHESISING INTERMEDIATES OF CRAMBESCIDINS AND CIMIPRONIDINE, AND DERIVATIVES THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2012-05-31 | — | — | WO | disclosed |
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | GLS, GLUL, HIF1A | TSHR 4058/4885HCAR2 400/4885KEAP1 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.